Evgen Pharma AI Stock Analysis
Want to see GB:TCF full AI Analyst Report?
Evgen Pharma (TCF) AI Stock Analysis
Evgen Pharma
(LSE:TCF)
The overall score is at the minimum of 37, reflecting a convergence of critical weaknesses. The most significant factor is the company's dire financial performance, marked by zero revenue, severe cash burn, and rapidly depleting equity, which threatens its viability. This is compounded by a bearish technical trend with the stock in a sustained downtrend and extremely weak momentum. The negative P/E ratio and lack of dividend yield provide no valuation support. The company faces an existential funding crisis with no positive catalysts evident.
Evgen Pharma (TCF) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 3.55M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.77M
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- 0.83
- Revenue Growth
- ―
- EPS Growth
- 55.56%
- Country
- UK
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Evgen Pharma Business Overview & Revenue Model
Company Description
Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase II...
How the Company Makes Money
Evgen Pharma is a clinical-stage biopharmaceutical company and, based on publicly available information, it does not appear to generate recurring product revenue from marketed drugs. Its typical monetization model is expected to be (i) partnering/lic...
Evgen Pharma Financial Statement Overview
Summary
Financial health is critically weak. The company is pre-revenue with zero sales, deeply negative margins, and consistent operating losses. Cash burn is severe, with operating cash flow of -£2.55M, and shareholder equity has eroded by 77% to just £2.7M. The only positive is negligible debt, but the rapid capital depletion poses an existential risk.
Income Statement
8Very NegativeBalance Sheet
42NeutralCash Flow
15Very Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 396.00K | 442.00K | 0 |
| Gross Profit | -16.00K | -16.00K | -2.11M | 385.00K | 429.00K | -16.00K |
| EBITDA | -3.62M | -3.67M | -2.06M | -3.55M | -4.99M | -3.15M |
| Net Income | -3.53M | -3.53M | -1.94M | -3.14M | -4.04M | -2.73M |
Balance Sheet | ||||||
| Total Assets | 4.81M | 4.81M | 7.63M | 3.06M | 6.17M | 9.64M |
| Cash, Cash Equivalents and Short-Term Investments | 1.54M | 1.54M | 4.11M | 2.00M | 5.00M | 9.03M |
| Total Debt | 11.00K | 11.00K | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.10M | 2.10M | 1.66M | 721.00K | 833.00K | 411.00K |
| Stockholders Equity | 2.72M | 2.72M | 5.97M | 2.34M | 5.34M | 9.23M |
Cash Flow | ||||||
| Free Cash Flow | -2.56M | -2.56M | -2.37M | -3.00M | -4.03M | -2.56M |
| Operating Cash Flow | -2.55M | -2.55M | -2.37M | -3.00M | -4.03M | -2.56M |
| Investing Cash Flow | 916.00K | 916.00K | -2.08M | 0 | 4.52M | 1.48M |
| Financing Cash Flow | -7,000 | -7,000 | 4.55M | 0 | 0 | 0 |
Evgen Pharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TCF, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.18, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 11.96 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TCF.
Evgen Pharma Peers Comparison
Overall Rating
GB:SAR47Neutral
GB:HEMO46Neutral
GB:VAL43Neutral
GB:SCLP42Neutral
GB:IMM39Underperform
GB:TCF37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | GBP 23.75M | -6.04 | -188.01% | ― | ― | 28.78% | |
| 46Neutral | GBP 46.21M | -3.70 | -409.57% | ― | ― | 18.57% | |
| 43Neutral | GBP 1.85M | -0.74 | -71.49% | ― | -34.36% | 57.45% | |
| 42Neutral | GBP 95.77M | -4.51 | 128.87% | ― | -100.00% | -30.39% | |
| 39Underperform | GBP 18.06M | -2.31 | -559.87% | ― | ― | 5.62% | |
| 37Underperform | GBP 4.51M | -1.65 | -93.92% | ― | ― | 55.56% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:TCF | Evgen Pharma | 0.17 | -0.02 | -13.16% | |
| GB:IMM | ImmuPharma plc | 2.90 | -3.81 | -56.79% | |
| GB:SAR | Sareum Holdings | 14.50 | 1.50 | 11.54% | |
| GB:SCLP | Scancell Holdings | 79.00 | -15.50 | -16.40% | |
| GB:HEMO | Hemogenyx Pharmaceuticals Plc | 670.00 | -10.00 | -1.47% | |
| GB:VAL | ValiRx plc | 0.14 | -0.11 | -45.10% |
Evgen Pharma Corporate Events
TheraCryf advances lead addiction drug to clinic-ready stage as losses widen
PositiveTheraCryf reported final results for the year to 31 March 2026, highlighting strong operational progress on its lead orexin-1 antagonist for addiction, which has advanced through late-stage preclinical development on time and budget. The company comp...
TheraCryf Sets Results Date as Lead Addiction Therapy Nears Clinical Readiness
PositiveTheraCryf plc, the biotech group developing treatments for addiction and neuropsychiatric conditions, is advancing a de-risked, best-in-class orexin-1 receptor antagonist through final pre-clinical trials and operates a virtual, partnership-focused d...
TheraCryf Wins Shareholder Backing for £1.05m Fundraise and Share Subdivision
PositiveTheraCryf plc, the biotech company developing treatments for addiction and other neuropsychiatric disorders, has secured shareholder approval for a capital raising of about £1.05 million through a placing and subscription. Investors also backed a sub...
TheraCryf raises £1.05m to advance addiction drug towards Phase 1 trials
PositiveTheraCryf plc has announced a proposed £1.05 million equity raise via a placing and subscription of new shares, priced at 0.18 pence each and directed to existing and new investors, to strengthen its balance sheet. The capital injection is intended t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 29, 2026